Advertisement

Advertisement

PCOWKIN Stock Latest News

OWKIN Expands Sanofi Alliance, Advances OKN4395 Trial and Showcases Reliability-Focused AI Platform

Private CompaniesOWKIN Expands Sanofi Alliance, Advances OKN4395 Trial and Showcases Reliability-Focused AI Platform

OWKIN Deepens Sanofi Collaboration With Multi-Year AI-Driven Biopharma Partnership

PremiumPrivate Companies

OWKIN Deepens Sanofi Collaboration With Multi-Year AI-Driven Biopharma Partnership

27d ago

Owkin Deepens Sanofi Collaboration With Multi-Year AI-Driven Biopharma Agreement

PremiumPrivate Companies

Owkin Deepens Sanofi Collaboration With Multi-Year AI-Driven Biopharma Agreement

27d ago

Owkin Highlights AI-Driven Longevity Research at Super Human Summit

PremiumPrivate Companies

Owkin Highlights AI-Driven Longevity Research at Super Human Summit

29d ago

OWKIN Highlights AI Strategy in Longevity and Aging Research

PremiumPrivate Companies

OWKIN Highlights AI Strategy in Longevity and Aging Research

29d ago

OWKIN Highlights New Reliability Metrics for K Pro AI System

PremiumPrivate CompaniesOWKIN Highlights New Reliability Metrics for K Pro AI System

30d ago

OWKIN Showcases AI Scientist Platform in Pulmonary Clinical Trials Forum

Private Companies

OWKIN Showcases AI Scientist Platform in Pulmonary Clinical Trials Forum

30d ago

OWKIN Highlights Reliability-Focused Evaluation Framework for K Pro AI System

Private Companies

OWKIN Highlights Reliability-Focused Evaluation Framework for K Pro AI System

1M ago

OWKIN Highlights New Clinical Supply Agreement and Combination Strategy for OKN4395

PremiumPrivate Companies

OWKIN Highlights New Clinical Supply Agreement and Combination Strategy for OKN4395

1M ago

OWKIN Enters Clinical Supply Collaboration for OKN4395 Combination Trial

PremiumPrivate Companies

OWKIN Enters Clinical Supply Collaboration for OKN4395 Combination Trial

1M ago

OWKIN Stresses Data-Validated AI and Rigorous Target Discovery in Oncology Push

PremiumPrivate Companies

OWKIN Stresses Data-Validated AI and Rigorous Target Discovery in Oncology Push

1M ago

OWKIN Highlights Data-Validation Framework for AI-Driven Life Science Tools

PremiumPrivate Companies

OWKIN Highlights Data-Validation Framework for AI-Driven Life Science Tools

1M ago

OWKIN Highlights Data-Validated AI Approach for Biological Discovery

PremiumPrivate CompaniesOWKIN Highlights Data-Validated AI Approach for Biological Discovery

1M ago

OWKIN Emphasizes Target Identification Rigor in Oncology Discovery

Private Companies

OWKIN Emphasizes Target Identification Rigor in Oncology Discovery

1M ago

OWKIN Highlights AI-Driven Target Identification Strategy in Oncology

Private Companies

OWKIN Highlights AI-Driven Target Identification Strategy in Oncology

1M ago

AI Adoption Trends in Biopharma Highlight Data, Regulation and Platform Needs

PremiumPrivate Companies

AI Adoption Trends in Biopharma Highlight Data, Regulation and Platform Needs

1M ago

AI Deployment Themes in Biopharma Highlight Data, Compliance and Platform Needs

PremiumPrivate Companies

AI Deployment Themes in Biopharma Highlight Data, Compliance and Platform Needs

1M ago

OWKIN Showcases AI-Driven ADC Target Prioritization in Bladder Cancer Program

PremiumPrivate Companies

OWKIN Showcases AI-Driven ADC Target Prioritization in Bladder Cancer Program

1M ago

OWKIN Showcases AI-Enabled ADC Target Prioritization in Bladder Cancer Discovery

PremiumPrivate Companies

OWKIN Showcases AI-Enabled ADC Target Prioritization in Bladder Cancer Discovery

1M ago

OWKIN – Weekly Recap

PremiumPrivate CompaniesOWKIN – Weekly Recap

1M ago

OWKIN Showcases AI-Driven Trial De-Risking Capabilities at Harvard Symposium

Private Companies

OWKIN Showcases AI-Driven Trial De-Risking Capabilities at Harvard Symposium

1M ago

OWKIN Showcases AI-Driven Trial De-Risking Platform at Harvard Symposium

Private Companies

OWKIN Showcases AI-Driven Trial De-Risking Platform at Harvard Symposium

1M ago

Trending

S&P 500

―

Dow Jones

―

Nasdaq 100

―

More Trending Stocks >